NIPPON SHOKUBAI CO., LTD.

Support for DDS Research and Drug Discovery

Our Services

  • [DDS]
    Cationic Peptide Conjugated with Folate Ligand (Fol-Dab8)

    Fol-Dab8 is innovative DDS technology that forms a complex when mixed with siRNA and delivers siRNA drugs to folate receptor-expressing cells (pancreatic cancer, brain tumors, breast cancer, etc.).
    *This technology was co-developed with Professor Takeshi Wada of Tokyo University of Science and Associate Professor Keisuke Taniuchi of Kochi University.

  • [DDS]
    New polymers for DDS

    We are developing polymers to overcome the concerns of polyethylene glycol (PEG), a widely used polymer for DDS. Nanoparticle formulations using our polymer offer a new solution in DDS.

  • Heteroduplex Oligonucleotides (HDO)

    Heteroduplex oligonucleotide (HDO) is the third platform technology for mRNA Therapeutics following short interfering RNA (siRNA) and single-stranded antisense oligonucleotide (ASO), which serves as a therapeutic agent for the modulation of specific genes at the post-transcriptional level. HDO is an artificial functioning nucleic acids composed of an antisense strand (gapmer, mixmer, PMO etc.) that binds to a transcript of a target gene and a carrier strand (RNA) that is complementary to the antisense strand. Since a ligand (receptor ligands, antibodies, lipids, etc.) is bound to the carrier strand, various ligands can be introduced without affecting the activity of the antisense strand enabling cell-specific delivery. HDO has high nuclear localization and low toxicity compared to ASO.

    • Rena Therapeutics uses heteroduplex oligonucleotide (HDO) technology as its base technology. HDO technology was co-developed by Professor Takanori Yokota of Tokyo Medical and Dental University and Professor Satoshi Obika of Osaka University.
    • Rena Therapeutics is a subsidiary of Nippon Shokubai.
  • Boranophosphate Oligonucleotides

    We are developing chemical synthesis techniques and practical manufacturing methods for boranophosphate oligonucleotides, which have a new structure to replace conventional phosphorothioate oligonucleotides. Boranophosphate oligonucleotides are expected to reduce the toxicity of oligonucleotide drugs.

  • Human-type Glycan-Modified Glucocerebrosidase

    This glycosylation enzyme has a uniform structure achieved by site-specific modification with human-type glycans. These changes are designed to transport the enzyme to specific cells and intracellular organelles, and give a stable pharmacological effect. This technology is the result of joint research with GlyTech, Inc.

    Glycoprotein
    with fully controlled
    glycan structures